Morgan Stanley maintained a Buy rating on Haleon plc, noting its growth in EMEA/LatAm and Asia-Pacific, while reporting a decline in North America, amidst the backdrop of Trump-era tariffs benefiting AI stocks.
2 reports, 2 independent
Updated Thu 00:00
No new developments lately
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Morgan Stanley maintained a Buy rating on Haleon plc, noting its growth in EMEA/LatAm and Asia-Pacific, while reporting a decline in North America, amidst the backdrop of Trump-era tariffs benefiting AI stocks.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Haleon faces soft demand and sales declines across North America, Europe, and China.1 source
Morgan Stanley rates Haleon plc a Buy, citing regional growth despite North American decline, amid AI stock benefits from Trump tariffs.1 source
Keep exploring
The entities involved
-
Haleon
British multinational consumer healthcare company
-
Morgan Stanley
U.S. investment bank
Coverage
Newest first; wire copies grouped- dailymail.com
- Insider MonkeyMorgan Stanley Maintains a Buy on Haleon plc (HLN) With a PT of $10.95 Haleon plc (NYSE:HLN) is one of the best NYSE stocks to buy under $20. In a report released on August 4, Morgan Stanley maintain